Fixed Drug Eruption and Generalized Bullous Fixed Drug Eruption: Insights from an Analysis of the FDA Adverse Event Reporting System

P. Shrestha; C.A. Stone Jr.; Elizabeth Phillips

doi:10.1016/j.jaip.2024.09.024

Back

Fixed Drug Eruption and Generalized Bullous Fixed Drug Eruption: Insights from an Analysis of the FDA Adverse Event Reporting System

Journal article

Open access

Peer reviewed

Fixed Drug Eruption and Generalized Bullous Fixed Drug Eruption: Insights from an Analysis of the FDA Adverse Event Reporting System

P. Shrestha, C.A. Stone Jr. and Elizabeth Phillips

The journal of allergy and clinical immunology. In practice, Vol.13(1), pp.236-237

2024

DOI: https://doi.org/10.1016/j.jaip.2024.09.024

Files and links (1)

pdf

Published427.14 kBDownload View

CC BY-NC-ND V4.0, Open Access

Abstract

This study underscores the necessity of increased vigilance and reporting for fixed drug eruption and generalized bullous fixed drug eruption, spotlighting common medications’ involvement and the significance of educating patients and health care professionals.

Details

Title: Fixed Drug Eruption and Generalized Bullous Fixed Drug Eruption: Insights from an Analysis of the FDA Adverse Event Reporting System
Authors/Creators: P. Shrestha
C.A. Stone Jr.
Elizabeth Phillips
Publication Details: The journal of allergy and clinical immunology. In practice, Vol.13(1), pp.236-237
Publisher: Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology
Identifiers: 991005703763807891
Murdoch Affiliation: Institute for Immunology and Infectious Diseases
Resource Type: Journal article

Metrics

28 Record Views